CD79A and COVID-19: Lastly, we determined the levels of IgA, IgG and IgM antibodies against SARS-CoV-2 nucleocapsid, spike proteins (spike 1 and spike 2), and receptor binding domain (RBD) in patients with different tumors and COVID-19 outcomes (Figure 4).